Medigene AG

Biotechnology ResearchGermany51-200 Employees

Medigene AG, based in Germany, operates in the biotechnology sector with a focus on immuno-oncology. It develops T-cell receptor-engineered T cells, or TCR-T therapies, to target cancer and maintains an end-to-end platform built on multiple proprietary development and enhancement technologies that aim to optimize safety and efficacy. The company pursues product candidates for its own pipeline as well as for external partnerships. Its customers primarily include pharmaceutical and biotech partners seeking next-generation TCR-T therapies, alongside Medigene's internal development efforts. In May 2026, the Champalimaud Foundation acquired a portfolio of Medigene's TCR programs, platform technologies, and related assets from Medigene Immunotherapies GmbH, and the deal included an exclusive license with Helmholtz Munich for key co-stimulatory receptor technologies.

Sign up for free to view info

Email Format Employee directory